Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma
Portfolio Pulse from
The European Medicines Agency's CHMP has recommended the approval of Sarclisa for treating transplant-ineligible newly diagnosed multiple myeloma in combination with VRd. This follows positive results from the IMROZ phase 3 study.
November 14, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sanofi's Sarclisa has been recommended for EU approval by the CHMP for treating transplant-ineligible newly diagnosed multiple myeloma, potentially expanding its market presence.
The CHMP's positive recommendation for Sarclisa in the EU is a significant regulatory milestone for Sanofi. If approved, it would be the first anti-CD38 therapy available in combination with VRd for NDMM patients, potentially increasing Sarclisa's market share and revenue.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100